Gene
MDM4
MDM4 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (14), Actionable biomarkers (1), Trial mentions (10), and 5 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention MDM4. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 1 of 8,597 | 0.01% | not measured | |
| 2023 | 2 of 8,275 | 0.02% | 4 of 11,460 | 0.03% |
| 2022 | 1 of 8,285 | 0.01% | 3 of 13,598 | 0.02% |
| 2021 | 0 of 8,692 | 0.00% | 4 of 15,045 | 0.03% |
| 2020 | 0 of 7,640 | 0.00% | 7 of 14,459 | 0.05% |
| 2019 | 3 of 7,300 | 0.04% | 9 of 12,159 | 0.07% |
| 2018 | 3 of 6,927 | 0.04% | 4 of 11,854 | 0.03% |
| 2017 | 0 of 6,558 | 0.00% | 4 of 11,595 | 0.03% |
Showing 10 of 37 years.
Assay-provider ledger (14)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Agilent Technologies | Reagent supplier | Clinical validation | 1 | March 01, 2025 |
| DAKO | Unclassified | Clinical validation | 1 | March 01, 2025 |
| Broad Institute | Not a company | Analytical validation | 1 | December 20, 2019 |
| Open Targets | Not a company | Analytical validation | 1 | December 20, 2019 |
| Wellcome Sanger Institute | Not a company | Analytical validation | 1 | December 20, 2019 |
Showing 5 of 14 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| MDM4 amplification | Mdm2/mdmx Inhibitors | response-associated | sarcoma | Cancer Genome Interpreter |
Trial mentions (10)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT05800340 | Trial eligibility (AACT) |
| NCT06058793 | Trial eligibility (AACT) |
| NCT03654716 | Trial eligibility (AACT) |
| NCT03725436 | Trial eligibility (AACT) |
| NCT03760445 | Trial eligibility (AACT) |
Showing 5 of 10 trial mentions.
Target-disease associations (348)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 22q11.2 deletion syndrome | cardiovascular disease | Mouse knockout (IMPC) |
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
| Alymphoid cystic thymic dysgenesis | immune system disease | Mouse knockout (IMPC) |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Atypical Meningioma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 348 associations.
Vendor sourcing (36)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The varaint is not observed in the gnomAD v2.1.1 dataset (PM2_M). A missense variant is a common mechanism associated with Bone marrow failure syndrome 6 (PP... | View ClinVar record SCV002058868.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.509A>G (p.E170G) alteration is located in exon 7 (coding exon 6) of the MDM4 gene. This alteration results from a A to G substitution at nucleotide pos... | View ClinVar record SCV003552914.2 |
| Boehringer Ingelheim (Germany) | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : 1. Known mutation in the TP53 gene (screening for TP53 status is not required) 2. Major surgery (major according to the investigator's assessment) perform... | View trial NCT06058793 |
| Boehringer Ingelheim (Germany) | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * Previous administration of BI 907828 or any other MDM2-p53 or MDMX (MDM4)-p53 antagonist * In Phase Ib (expansion phase) and Phase Ia expansion cohort o... | View trial NCT03964233 |
| Boehringer Ingelheim (Germany) | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * Previous administration of brigimadlin (BI 907828) or any other MDM2-p53 or mouse double minute 4 (MDMX, MDM4)-p53 antagonist. * Active bleeding, signif... | View trial NCT05512377 |
Showing 5 of 36 sourcing records.
Trial-cited literature (60)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| p53 stabilisation potentiates [<sup>177</sup>Lu]Lu-DOTATATE treatment in neuroblastoma xenografts. | European journal of nuclear medicine and molecular imaging | 2024 | 5 |
| Drugging p53 in cancer: one protein, many targets. | Nature reviews. Drug discovery | 2023 | 569 |
| A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. | Blood cancer journal | 2023 | 21 |
| Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. | Cell reports. Medicine | 2023 | 8 |
| TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia. | Biomedicines | 2023 | 6 |
Showing 5 of 60 papers.
Literature-extracted relations (2)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Leukemia | Disease | associate |
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. | 2018 |
| Hypoxia, Brain | Disease | associate |
Hypoxia downregulates p53 but induces apoptosis and enhances expression of BAD in cultures of human syncytiotrophoblasts. | 2010 |
Organizations publishing (107)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 5 | 2015 to 2022 |
| Vanderbilt Health | Industry | 3 | 2020 to 2021 |
| Asan Foundation | Nonprofit | 2 | 2016 to 2022 |
| Chinese Academy of Medical Sciences & Peking Union Medical College | Academic | 2 | 2019 to 2023 |
| Dana-Farber Cancer Institute | Other | 2 | 2019 to 2020 |
Showing 5 of 107 organizations.
Where MDM4 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- integumentary system disease
- measurement
- nervous system disease
- nutritional or metabolic disease
- phenotype
- respiratory or thoracic disease
- urinary system disease
306 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, protein variant mentions, and human sample screening reference.